Rakesh Jhujhunwala’s wealth grows Rs 181 cr in 1 hour on his favourite stock

The surge in stock price to Rs 1,089 per share on Monday morning has helped ace investor Rakesh Jhunjhunwala, who holds 3.93 crore shares of the company, pocket gains worth Rs 180.8 crore.

Titan Company limited shares jumped 4.15% after the company announced a dividend of Rs 4 per share on Monday morning. Shares of the watch and jewellery manufacturer have managed to surge 33% since the March lows. The surge in stock price to Rs 1,089 per share on Monday morning has helped ace investor Rakesh Jhunjhunwala, who holds 3.93 crore shares of the company, pocket gains worth Rs 180.8 crore in little over an hour since the opening bell. Rakesh Jhunjhunwala has been an investor in the company for decades now and Titan is often touted as his favourite stock.

Shares of the company ended Friday’s trading session at a price of Rs 1,043 per share. Rakesh Jhunjhunwala at the end of April-June quarter held 3,93,10,395 shares of the company, as per the data available on the bourses. His total investment in Titan was valued at Rs 4,100 crore when stock exchanges closed for trading on Friday. As Monday’s session began and Titan’s share price soared higher, the Big Bull’s investment in the company increased to Rs 4,280 crore. Adding Rs 180.8 crore to the investment value.

Along with Rakesh Jhunjhunwala his wife, Rekha Jhunjhunwala, too owns a significant stake in the company with 97,40,575 shares in her name. Rekha Jhunjhunwala too gained from the jump in Titan stock, increasing her wealth by Rs 44.8 crore. Combined the Jhujhunwala’s hold 4.90 crore shares of Titan Company Limited or 5.53% of the total share capital. Their investment in the company stands at over Rs 5,300 crore.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog